🇺🇸 FDA

Drug profile · INN

datopotamab deruxtecan-dlnk

DATROWAY

approved
US status
approved
Patents linked
0
News articles
1

Quick answer

datopotamab deruxtecan-dlnk (DATROWAY) is an FDA-listed pharmaceutical active ingredient. Route of administration: iv (infusion). Current US regulatory status: approved.

Key facts

INN datopotamab deruxtecan-dlnk
Brand DATROWAY
Route IV (INFUSION)
Formulation INJECTABLE

Frequently asked questions

What is datopotamab deruxtecan-dlnk?

datopotamab deruxtecan-dlnk (DATROWAY) is an FDA-listed pharmaceutical active ingredient. Route of administration: iv (infusion). Current US regulatory status: approved.

What is the brand name for datopotamab deruxtecan-dlnk?

DATROWAY is a marketed brand name for datopotamab deruxtecan-dlnk. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of datopotamab deruxtecan-dlnk?

datopotamab deruxtecan-dlnk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.